Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

ER-positive breast cancer patients do not usually respond to immunotherapy. In this phase II clinical trial, the authors report the safety and efficacy of combining vorinostat and pembrolizumab with tamoxifen in ER-positive breast cancers and provide evidence that T-cell exhaustion may serve as a po...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Manuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, Mark Moasser, Amy J. Chien, Michelle E. Melisko, Hope Rugo, Roshun Rahimi, Travis Deal, Adil Daud, Michael D. Rosenblum, Scott Thomas, Pamela N. Munster
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:64f0fec706954f5c93dba4c047a3944a
record_format	dspace
spelling	oai:doaj.org-article:64f0fec706954f5c93dba4c047a3944a2021-12-02T17:01:15ZExhausted T cell signature predicts immunotherapy response in ER-positive breast cancer10.1038/s41467-020-17414-y2041-1723https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a2020-07-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-17414-yhttps://doaj.org/toc/2041-1723ER-positive breast cancer patients do not usually respond to immunotherapy. In this phase II clinical trial, the authors report the safety and efficacy of combining vorinostat and pembrolizumab with tamoxifen in ER-positive breast cancers and provide evidence that T-cell exhaustion may serve as a potential signature for the response of this combination therapy.Manuela Terranova-BarberioNela PawlowskaMallika DhawanMark MoasserAmy J. ChienMichelle E. MeliskoHope RugoRoshun RahimiTravis DealAdil DaudMichael D. RosenblumScott ThomasPamela N. MunsterNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Manuela Terranova-Barberio Nela Pawlowska Mallika Dhawan Mark Moasser Amy J. Chien Michelle E. Melisko Hope Rugo Roshun Rahimi Travis Deal Adil Daud Michael D. Rosenblum Scott Thomas Pamela N. Munster Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
description	ER-positive breast cancer patients do not usually respond to immunotherapy. In this phase II clinical trial, the authors report the safety and efficacy of combining vorinostat and pembrolizumab with tamoxifen in ER-positive breast cancers and provide evidence that T-cell exhaustion may serve as a potential signature for the response of this combination therapy.
format	article
author	Manuela Terranova-Barberio Nela Pawlowska Mallika Dhawan Mark Moasser Amy J. Chien Michelle E. Melisko Hope Rugo Roshun Rahimi Travis Deal Adil Daud Michael D. Rosenblum Scott Thomas Pamela N. Munster
author_facet	Manuela Terranova-Barberio Nela Pawlowska Mallika Dhawan Mark Moasser Amy J. Chien Michelle E. Melisko Hope Rugo Roshun Rahimi Travis Deal Adil Daud Michael D. Rosenblum Scott Thomas Pamela N. Munster
author_sort	Manuela Terranova-Barberio
title	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
title_short	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
title_full	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
title_fullStr	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
title_full_unstemmed	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
title_sort	exhausted t cell signature predicts immunotherapy response in er-positive breast cancer
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a
work_keys_str_mv	AT manuelaterranovabarberio exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer AT nelapawlowska exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer AT mallikadhawan exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer AT markmoasser exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer AT amyjchien exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer AT michelleemelisko exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer AT hoperugo exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer AT roshunrahimi exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer AT travisdeal exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer AT adildaud exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer AT michaeldrosenblum exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer AT scottthomas exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer AT pamelanmunster exhaustedtcellsignaturepredictsimmunotherapyresponseinerpositivebreastcancer
_version_	1718382210583625728

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

Ejemplares similares